Group One Trading’s Keros Therapeutics KROS Stock Holding History

Group One Trading’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,500	Closed	-$295K	–	8208
2025 Q4	$295K	Sell	14,500 -400	-3%	-$7.02K	﹤0.01%	4026
2025 Q3	$236K	Buy	14,900 +900	+6%	+$13.3K	﹤0.01%	4506
2025 Q2	$187K	Sell	14,000 -70,200	-83%	-$948K	﹤0.01%	4415
2025 Q1	$858K	Buy	84,200 +81,800	+3,408%	+$950K	﹤0.01%	2595
2024 Q4	$38K	Buy	+2,400	New	+$125K	﹤0.01%	5263
2024 Q3	–	Sell	-200	Closed	-$9.14K	–	7002
2024 Q2	$9.14K	Buy	200 +100	+100%	+$5.37K	﹤0.01%	5678
2024 Q1	$6.62K	Buy	+100	New	+$5.93K	﹤0.01%	6072
2023 Q2	–	Sell	-24,500	Closed	-$1.05M	–	7945
2023 Q1	$1.05M	Buy	24,500 +7,500	+44%	+$379K	﹤0.01%	2100
2022 Q4	$816K	Buy	17,000 +1,900	+13%	+$88.8K	﹤0.01%	2602
2022 Q3	$568K	Buy	+15,100	New	+$523K	﹤0.01%	3115

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Group One Trading's KROS Position: Q2 2026 in Review

Group One Trading reduced its Keros Therapeutics (KROS) stake by 87% in Q2 2026, selling an estimated $7.07K and leaving 99 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #7173.

Group One Trading first reported a position in KROS in Q2 2022 and has held it in 7 quarters since. The position peaked at $506K in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Group One Trading held 99 shares of Keros Therapeutics worth $1.06K as of Q2 2026.
Group One Trading sold 635 Keros Therapeutics shares in Q2 2026, an estimated $7.07K.
Keros Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7173 holding.
Group One Trading first reported a position in Keros Therapeutics in Q2 2022 and has held it in 7 quarters since.
Group One Trading's Keros Therapeutics position peaked at $506K in Q1 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.